ArticleNPJ digital medicine2025
Alzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- AI and Internet of Things for Chronic Obstructive Pulmonary Disease Remote Monitoring: Systematic Review of Exacerbation Prediction and Key Physiological Variables.JMIR medical informatics · 2026Pooled it
- From immunological mechanisms to targeted therapies: a bibliometric analysis in the domain of research concerning neutrophil extracellular traps and pulmonary diseases (2006-2025).Frontiers in immunology · 2026Pooled it
- Operationalizing Alzheimer's disease trials in the era of targeted therapies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Clinical trial landscape of cell therapy for spinal cord injury: from integrated practices to future developments.BMC medicine · 2026Article
- The myth of digital biomarkers in Alzheimer's disease: how to make them a reality.Current opinion in psychiatry · 2026Review
- Mulberroside A Alleviates Scopolamine-Induced Cognitive Deficits by Suppressing Neuroinflammation and Oxidative Stress via theBiology · 2026Article
- Bridging neuroinflammation, oxidative stress, and neurogenesis: aromatic turmerone as a multifunctional modulator via NF-κB and Nrf2 pathways.Inflammopharmacology · 2026Review
- AI-driven big data analysis and predictive modeling of infectious disease immunity: from correlates to causal, multiscale understanding.Archives of microbiology · 2026Review
- Speech-based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Artificial intelligence in nursing practice for older adults with dementia: A narrative review informed by bibliometric mapping and implications for nurse-led research.Journal of Korean gerontological nursing · 2026Article
- Multi-Target-Directed Ligands (MTDLs) as Potential Therapeutic Candidates Targeting Multiple Pathogenic Factor of Alzheimer's Disease.CNS neuroscience & therapeutics · 2026Review
- Application of Deep Multi-Scale Representation Learning Based on Eye-Tracking and Facial Expression Data in Cognitive Decline Assessment.Sensors (Basel, Switzerland) · 2026Article
- A framework of digital biomarkers for neurodegenerative diseases.Nature reviews bioengineering · 2026Article
- Epigenetic and Transcriptomic Pathways Underlying Animal Models of Cognitive and Psychiatric Disorders: A Scoping Review.Current issues in molecular biology · 2026Review
- Research on Threshold Optimization and Variability-Based Digital Biomarker Approaches Through MMSE-Lifelog Multimodal Integrated Analysis from a Clinical Screening Perspective.Healthcare (Basel, Switzerland) · 2026Article
- A parsimonious six-predictor model for memory decline: cross-population validation in Chinese and Japanese aging cohorts.GeroScience · 2026Article
- Artificial intelligence-based biomarkers for the diagnosis and treatment of neurological conditions: a narrative review.Molecular brain · 2026Review
- Value of lncRNA LINC00641 as a Potential Biomarker for Diagnosis of Alzheimer's Disease and Elucidation of its Underlying Molecular Mechanism.Journal of molecular neuroscience : MN · 2026Article
- Recent Advances in AI and GenAI for Health Informatics.Healthcare (Basel, Switzerland) · 2026Review
- Immunometabolism Reframes Alzheimer's Disease: From Systemic Dysmetabolism to Glial Rewiring.Cellular and molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
As digital biomarkers gain traction in Alzheimer's disease (AD) diagnosis, understanding recent advancements is crucial. This review conducts a bibliometric analysis of 431 studies from five online databases: Web of Science, PubMed, Embase, IEEE Xplore, and CINAHL, and provides a scoping review of 86 artificial intelligence (AI) models. Research in this field is supported by 224 grants across 54 disciplines and 1403 institutions in 44 countries, with 2571 contributing researchers. Key focuses include motor activity, neurocognitive tests, eye tracking, and speech analysis. Classical machine learning models dominate AI research, though many lack performance reporting. Of 21 AD-focused models, the average AUC is 0.887, while 45 models for mild cognitive impairment show an average AUC of 0.821. Notably, only 2 studies incorporated external validation, and 3 studies performed model calibration. This review highlights the progress and challenges of integrating digital biomarkers into clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.